180 Life Sciences Corp. has reported the exercise of pre-funded warrants on March 6 and 7, 2024, resulting in the issuance of 72,000 and 62,000 shares of common stock, respectively. This follows the company's 1-for-19 reverse stock split effective on February 28, 2024. The transactions, which involved an aggregate cash amount of $254.60, were exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Following these exercises, the company announced that no pre-funded warrants remain outstanding and the total issued and outstanding common stock amounts to approximately 852,758 shares. The resale of the shares was registered under a registration statement declared effective under the Securities Act. The information was disclosed in a Form 8-K filed with the SEC, signed by CEO James N. Woody, M.D., Ph.D., on March 8, 2024.

180 Life Sciences Corp. has reported the exercise of pre-funded warrants on March 6 and 7, 2024, resulting in the issuance of 72,000 and 62,000 shares of common stock, respectively. This follows the company's 1-for-19 reverse stock split effective on February 28, 2024. The transactions, which involved an aggregate cash amount of $254.60, were exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Following these exercises, the company announced that no pre-funded warrants remain outstanding and the total issued and outstanding common stock amounts to approximately 852,758 shares. The resale of the shares was registered under a registration statement declared effective under the Securities Act. The information was disclosed in a Form 8-K filed with the SEC, signed by CEO James N. Woody, M.D., Ph.D., on March 8, 2024.